INIFY Laboratories

INIFY Laboratories Current Assets

The Current Assets of INIFY Laboratories (INIFY.OL) as of Oct 28, 2026 is 1.72 M SEK. In the previous year, Current Assets was 914,000.00 SEK — a change of 87.86% (higher).

Current Assets

1.72 MSEK

YoY

87.86%

Last updated:

Current Assets of INIFY Laboratories is 2025 1.72 M SEK. Current Assets of INIFY Laboratories was 2024 914,000.00 SEK. It decreases by 87.86% higher compared to the previous year.

The INIFY Laboratories Current Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Current Assets
Date
Current Assets
Jan 1, 2021
0.00 SEK
Jan 1, 2022
88,000.00 SEK
Jan 1, 2023
272,000.00 SEK
Jan 1, 2024
914,000.00 SEK
Jan 1, 2025
1.72 M SEK
The INIFY Laboratories Current Assets history
YEARCurrent AssetsYoY
1.72 MSEK+87.86%
914,000.00SEK+236.03%
272,000.00SEK+209.09%
88,000.00SEK—
0.00SEK—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

INIFY Laboratories Stock analysis

What does INIFY Laboratories do? INIFY Laboratories AB generates revenue through providing cancer diagnostics via digital pathology services. The company offers two primary services: Full pathology Reports signed by INIFY's subspecialized pathologists and Whole Slide Images (WSI) with Pathology Decision Support Tool (PDST) analysis results. These services target healthcare providers and institutions requiring efficient, AI-optimized diagnostics for prostate biopsies. The firm's Solna, Sweden laboratory handles the entire sample processing chain, from logistics to reporting, leveraging AI to enhance quality and speed. INIFY's workflow is fully digital and standardized, initially focusing on prostate diagnostics. The company's service model includes both direct reporting by INIFY pathologists and WSI generation with PDST analysis, catering to clients seeking streamlined pathology solutions. This approach differentiates INIFY from traditional pathology services by integrating AI support throughout the diagnostic process. The business originates from ContextVision, indicating a foundation in digital pathology innovation. INIFY's offerings are designed to optimize response times and quality in prostate biopsy analysis, serving healthcare organizations that require advanced diagnostic tools without managing the full pathology workflow internally. INIFY Laboratories is one of the most popular companies on Eulerpool.

Frequently Asked Questions about INIFY Laboratories stock

Current Assets of INIFY Laboratories is 1.72 M SEK in 2025.

Current Assets of INIFY Laboratories changed from 914,000.00 SEK to 1.72 M SEK, representing a 87.86% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Current Assets INIFY Laboratories since 2006 – with annual values, charts, and detailed analysis.

Current assets are assets expected to be converted to cash within one year, including cash, receivables, and inventory.

Current Assets's SEK is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Current Assets's INIFY Laboratories historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Balance Sheet — INIFY Laboratories

All Key Metrics — INIFY Laboratories